Table 2. Genotype analysis of LEPR, eNOS, KDR, miR-27a, miR-449b and TNF-α polymorphisms in RPL patients and controls.
| Genotype | Controls (n = 50) | RPL patients (n = 53) | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| LEPR rs1137101(G>A) | |||||
| GG | 37 (74.0) | 38 (71.7) | 1.00 | ||
| GA | 12 (24.0) | 15 (28.3) | 1.22 (0.50–2.95) | 0.663 | |
| AA | 1 (2.0) | 0 | 0.32 (0.01–8.23) | 0.495 | |
| Dominant (GG vs. GA+AA) | 1.12 (0.47–2.68) | 0.793 | |||
| Recessive (GG+GA vs. AA) | 0.31 (0.01–7.75) | 0.475 | |||
| LEPR rs7516341(T>C) | |||||
| CC | 37 (74.0) | 47 (88.7) | 0.42 (0.02–10.66) | 0.601 | |
| TC | 13 (26.0) | 5 (9.4) | 0.14 (0.00–3.87) | 0.243 | |
| TT | 0 | 1 (1.9) | 1.00 | ||
| Dominant (TT vs. TC+CC) | 0.35 (0.01–8.71) | 0.519 | |||
| Recessive (TT+TC vs. CC) | 2.75 (0.95–7.94) | 0.061 | |||
| eNOS rs1799983(G>T) | |||||
| GG | 44 (88.0) | 43 (81.1) | 1.00 | ||
| GT | 6 (12.0) | 8 (15.1) | 1.36 (0.44–4.26) | 0.593 | |
| TT | 0 | 2 (3.8) | 5.11 (0.24–109.64) | 0.297 | |
| Dominant (GG vs. GT+TT) | 1.71 (0.57–5.10) | 0.340 | |||
| Recessive (GG+GT vs. TT) | 4.90 (0.23–104.69) | 0.309 | |||
| KDR rs2071559(T>C) | |||||
| TT | 23 (46.0) | 27 (50.9) | 1.00 | ||
| TC | 19 (38.0) | 24 (45.3) | 1.08 (0.47–2.44) | 0.861 | |
| CC | 8 (16.0) | 2 (3.8) | 0.21 (0.04–1.10) | 0.066 | |
| Dominant (TT vs. TC+CC) | 0.82 (0.38–1.78) | 0.616 | |||
| Recessive (TT vs. TC+CC) | 0.21 (0.04–1.02) | 0.053 | |||
| miR-27a rs895819(A>G) | |||||
| AA | 23 (46.0) | 24 (45.3) | 1.00 | ||
| AG | 24 (48.0) | 21 (39.6) | 0.84 (0.37–1.90) | 0.673 | |
| GG | 3 (6.0) | 8 (15.1) | 2.56 (0.60–10.84) | 0.203 | |
| Dominant (AA vs. AG+GG) | 1.03 (0.47–2.24) | 0.942 | |||
| Recessive (AA vs. AG+GG) | 2.79 (0.69–11.17) | 0.148 | |||
| miR-449b rs10061133(A>G) | |||||
| AA | 30 (60.0) | 22 (41.5) | 1.00 | ||
| AG | 16 (32.0) | 28 (52.8) | 2.39 (1.05–5.44) | 0.039* | |
| GG | 4 (8.0) | 3 (5.7) | 1.02 (0.21–5.04) | 0.978 | |
| Dominant (AA vs. AG+GG) | 2.11 (0.96–4.64) | 0.062 | |||
| Recessive (AA vs. AG+GG) | 0.69 (0.15–3.25) | 0.639 | |||
| TNF-α rs1800630(C>A) | |||||
| CC | 37 (74.0) | 34 (64.2) | 1.00 | ||
| CA | 11 (22.0) | 14 (26.4) | 1.39 (0.55–3.46) | 0.486 | |
| AA | 2 (4.0) | 5 (9.4) | 2.72 (0.49–14.96) | 0.250 | |
| Dominant (CC vs. CA+AA) | 1.59 (0.68–3.70) | 0.282 | |||
| Recessive (CC+CA vs. AA) | 2.50 (0.46–13.52) | 0.287 | |||
Values are presented as number (%) of cases.
eNOS = endothelial nitric oxide synthase, KDR = kinase insert domain-containing receptor, TNF = tumor necrosis factor, RPL = recurrent pregnancy loss, OR = odds ratio; CI = confidence interval.
*P < 0.05.